

AMENDMENT TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (withdrawn-currently amended) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) precipitating amorphous valsartan from a solution of valsartan in ~~a solvent selected from the group consisting of methyl t-butyl ether and acetone~~; and
 - b) recovering valsartan amorphous form, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g.
2. Canceled
3. (withdrawn) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) precipitating amorphous valsartan from a mixture of water and a solvent selected from the group consisting of ethanol, DMF, acetone and mixtures thereof; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g.
4. (withdrawn) The process of claim 3, wherein precipitating is carried out by combining water as an anti-solvent with the solution of valsartan in the solvent.
5. (withdrawn-currently amended) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) preparing a solution of valsartan in a solvent selected from the group consisting of tetrahydrofuran, dioxane, ethanol, isopropanol, and diethyl ether ~~and methanol~~; and
 - b) removing the solvent to obtain the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g.

6. (withdrawn) The process of claim 5, wherein removing is carried out by evaporation.
7. (canceled)
8. (withdrawn-currently amended) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) suspending valsartan in ~~a solvent selected from the group consisting of water and C₅-to-C₁₂-saturated hydrocarbon~~ to obtain amorphous valsartan; and
 - b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g.
9. (withdrawn) The process of claim 8, wherein the suspending step includes heating.
10. (Canceled)
11. (Canceled)
12. (withdrawn-currently amended) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) acidifying a basic aqueous solution of valsartan, wherein the acidifying results in precipitation of amorphous valsartan; and
 - b) recovering the precipitated amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g.
13. (withdrawn) The process of claim 12, wherein the acidifying results in a pH of from about 2 to about 5.
14. (withdrawn-currently amended) A process for preparing amorphous form of valsartan comprising the steps of:
 - a) heating valsartan in diisopropyl ether to obtain amorphous valsartan; and

- b) recovering the amorphous valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g..

15. (Canceled)

16. (Canceled)

17. (original) Amorphous form of valsartan, wherein the amorphous form has a DSC thermogram that lacks a melting point above about 1 J/g.

18. (canceled)

19-80. (canceled)

81. (withdrawn-currently amended) A pharmaceutical composition comprising amorphous valsartan of claim 17 ~~in the solid state with a thermogram lacking a melting point above about 1 J/g,~~ and a pharmaceutically acceptable excipient.

82. (withdrawn-currently amended) A method for treating hypertension in a mammal comprising the step of administering the pharmaceutical composition of claim 82 ~~82~~ 81 to the mammal in need thereof.

83-85. (canceled)